Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles
复制标题
DOI：
10.1007/s10637-008-9137-0
复制
发表时间：
2008-08-01
影响因子：
3.4
通讯作者：
Remick, Scot C.
中科院分区：
文献类型：
--
作者：
Sanborn, Sharon L.;Cooney, Matthew M.;Remick, Scot C.
目的：临床前模型已证明细胞毒性化疗联合抗血管生成化合物的节律性方案的益处。该试验的目的是确定使用多西他赛和沙利度胺的低剂量方案的毒性。患者和方法：纳入患有晚期实体瘤的患者。沙利度胺 100mg 每日两次，多西紫杉醇剂量从 10mg/m(2)/周逐渐增加至 30mg/m(2)/周。一个周期包括连续 12 周的治疗。最大耐受剂量（MTD）定义为沙利度胺与多西他赛引起的剂量
Purpose: Pre-clinical models have demonstrated the benefit of metronomic schedules of cytotoxic chemotherapy combined with anti-angiogenic compounds. This trial was undertaken to determine the toxicity of a low dose regimen using docetaxel and thalidomide. Patients and Methods: Patients with advanced solid tumors were enrolled. Thalidomide 100mg twice daily was given with escalating doses of docetaxel from 10 to 30mg/m(2)/week. One cycle consisted of 12 consecutive weeks of therapy. The maximal tolerated dose (MTD) was defined as the dose of thalidomide along with docetaxel that caused